{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:47:51Z","timestamp":1770673671483,"version":"3.49.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>Stenotrophomonas maltophilia is an emerging multidrug-resistant opportunistic pathogen, frequently recovered from deep sites in immunocompromised or critically ill patients. Its clinical relevance is difficult to distinguish from colonization, particularly in polymicrobial infections. To describe the management of patients with deep-site S. maltophilia isolates and to identify factors associated with 28-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a bicentric retrospective study including all patients with at least one deep-site S. maltophilia isolates in two Paris academic hospitals between 2018 and 2020. Demographic, clinical, microbiological and therapeutic data were collected. Appropriate therapy was defined upon in vitro susceptibility. Propensity score weighting was applied to adjust for confounding when assessing the association between appropriate therapy and 28-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 131 patients were included (67% male; median age 61\u2005years); 63% were immunocompromised and 31% admitted to intensive care. Isolates originated mainly from urine (41%), blood (32%) and respiratory samples (21%); 57% of cultures were polymicrobial. Appropriate therapy was administered to 53% of patients, predominantly trimethoprim\/sulfamethoxazole or fluoroquinolones. Overall 28-day mortality was 20%. Mechanical ventilation was independently associated with mortality (HR 4.13, P\u200a=\u200a0.001). After propensity score weighting, appropriate therapy was not significantly associated with improved survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Targeted therapy against S. maltophilia did not reduce 28-day mortality after adjustment, suggesting that patient condition and infection severity may outweigh the effect of targeted treatment. Given the modest sample size, potential confounding, and the secondary nature of this analysis, these findings should be interpreted with caution. Careful clinical evaluation is warranted before initiating specific S. maltophilia therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag021","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:34:52Z","timestamp":1768048492000},"source":"Crossref","is-referenced-by-count":0,"title":["Management and outcomes of\n                    <i>Stenotrophomonas maltophilia<\/i>\n                    recovered from deep-site clinical specimens: a bicentric retrospective cohort study"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-6413","authenticated-orcid":false,"given":"Anastasia","family":"Saade","sequence":"first","affiliation":[{"name":"Service de maladies infectieuses, Universit\u00e9 C\u00f4te d'Azur, CHU Nice , Nice 06202 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Pilmis","sequence":"additional","affiliation":[{"name":"Service de Microbiologie Clinique et plateforme de dosage des anti-infectieux, H\u00f4pitaux Saint-Joseph et Marie-Lannelongue , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6323-5910","authenticated-orcid":false,"given":"Herv\u00e9","family":"Jacquier","sequence":"additional","affiliation":[{"name":"Service de Bact\u00e9riologie, H\u00f4pital Henri Mondor, Assistance Publique des h\u00f4pitaux de Paris , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Lafaurie","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Maladies infectieuses et tropicales, H\u00f4pital Saint-Louis-Lariboisi\u00e8re, Assistance Publique des h\u00f4pitaux de Paris , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Sellier","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Maladies infectieuses et tropicales, H\u00f4pital Saint-Louis-Lariboisi\u00e8re, Assistance Publique des h\u00f4pitaux de Paris , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Michonneau","sequence":"additional","affiliation":[{"name":"Service d\u2019h\u00e9matologie greffe adulte, H\u00f4pital Saint-Louis, Assistance Publique des h\u00f4pitaux de Paris , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lebeaux","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Maladies infectieuses et tropicales, H\u00f4pital Saint-Louis-Lariboisi\u00e8re, Assistance Publique des h\u00f4pitaux de Paris , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1603-3635","authenticated-orcid":false,"given":"B\u00e9atrice","family":"Ber\u00e7ot","sequence":"additional","affiliation":[{"name":"Service de Bact\u00e9riologie, H\u00f4pital Saint-Louis Lariboisi\u00e8re, Assistance Publique des h\u00f4pitaux de Paris, INSERM, UMR1137, IAME , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Lise","family":"Munier","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Maladies infectieuses et tropicales, H\u00f4pital Saint-Louis-Lariboisi\u00e8re, Assistance Publique des h\u00f4pitaux de Paris , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2026020510355426200_dkag021-B1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1473-3099(09)70083-0","article-title":"Stenotrophomonas maltophilia: an emerging opportunist human pathogen","volume":"9","author":"Looney","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2026020510355426200_dkag021-B2","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1186\/cc5063","article-title":"Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome","volume":"10","author":"Nseir","year":"2006","journal-title":"Crit Care"},{"key":"2026020510355426200_dkag021-B3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/23744235.2018.1531145","article-title":"Stenotrophomonas maltophilia\u2014a low-grade pathogen with numerous virulence factors","volume":"51","author":"Trifonova","year":"2019","journal-title":"Infect Dis"},{"key":"2026020510355426200_dkag021-B4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5005\/jp-journals-10071-23241","article-title":"Stenotrophomonas maltophilia: more than just a colonizer!","volume":"23","author":"Baidya","year":"2019","journal-title":"Indian J Crit Care Med"},{"key":"2026020510355426200_dkag021-B5","doi-asserted-by":"publisher","first-page":"e924577","DOI":"10.12659\/AJCR.924577","article-title":"Stenotrophomonas maltophilia infection in a patient with acute exacerbation of chronic obstructive pulmonary disease (COPD): a colonizer or true infection?","volume":"21","author":"Oladunjoye","year":"2020","journal-title":"Am J Case Rep"},{"key":"2026020510355426200_dkag021-B6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/MCP.0b013e328358d4f8","article-title":"Stenotrophomonas maltophilia: to be or not to be a cystic fibrosis pathogen","volume":"18","author":"Hansen","year":"2012","journal-title":"Curr Opin Pulm Med"},{"key":"2026020510355426200_dkag021-B7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jhin.2013.09.007","article-title":"Outbreak of Stenotrophomonas maltophilia on an intensive care unit","volume":"85","author":"Guyot","year":"2013","journal-title":"J Hosp Infect"},{"key":"2026020510355426200_dkag021-B8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/ijccm.IJCCM_106_18","article-title":"Resurgence of global opportunistic multidrug-resistant Stenotrophomonas maltophilia","volume":"22","author":"Gupta","year":"2018","journal-title":"Indian J Crit Care Med"},{"key":"2026020510355426200_dkag021-B9","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3389\/fmicb.2017.01511","article-title":"Editorial: a multidisciplinary Look at Stenotrophomonas maltophilia: an emerging multi-drug-resistant global opportunistic pathogen","volume":"8","author":"Brooke","year":"2017","journal-title":"Front Microbiol"},{"key":"2026020510355426200_dkag021-B10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10096-009-0709-5","article-title":"Community-acquired Stenotrophomonas maltophilia infections: a systematic review","volume":"28","author":"Falagas","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026020510355426200_dkag021-B11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jinf.2012.01.001","article-title":"Stenotrophomonas maltophilia\u2013the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study","volume":"64","author":"Fihman","year":"2012","journal-title":"J Infect"},{"key":"2026020510355426200_dkag021-B12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/bmt.2012.87","article-title":"Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage","volume":"48","author":"Tada","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026020510355426200_dkag021-B13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1399-3062.2011.00710.x","article-title":"Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy","volume":"14","author":"Araoka","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"2026020510355426200_dkag021-B14","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026020510355426200_dkag021-B15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jgar.2024.05.016","article-title":"Trimethoprim-sulfamethoxazole versus levofloxacin for the treatment of Stenotrophomonas maltophilia infections: a multicentre cohort study","volume":"38","author":"Almangour","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"2026020510355426200_dkag021-B16","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/antibiotics12050910","article-title":"Stenotrophomonas maltophilia infections: a systematic review and meta-analysis of comparative efficacy of available treatments, with critical assessment of novel therapeutic options","volume":"12","author":"Maraolo","year":"2023","journal-title":"Antibiotics"},{"key":"2026020510355426200_dkag021-B17","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.cmi.2025.04.031","article-title":"How do I manage a patient with Stenotrophomonas maltophilia infection?","volume":"31","author":"Monardo","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026020510355426200_dkag021-B18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jhin.2008.05.020","article-title":"Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review","volume":"70","author":"Paez","year":"2008","journal-title":"J Hosp Infect"},{"key":"2026020510355426200_dkag021-B19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2026020510355426200_dkag021-B20","author":"Hennet"},{"key":"2026020510355426200_dkag021-B21","doi-asserted-by":"publisher","first-page":"102829","DOI":"10.1016\/j.jiph.2025.102829","article-title":"Risk factors for mortality and implications on therapy for Stenotrophomonas maltophilia bacteraemia","volume":"18","author":"Koh","year":"2025","journal-title":"J Infect Public Health"},{"key":"2026020510355426200_dkag021-B22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10096-010-0882-6","article-title":"Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996\u20132009","volume":"29","author":"Araoka","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026020510355426200_dkag021-B23","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4266\/acc.2023.00682","article-title":"Risk factors for mortality in intensive care unit patients with Stenotrophomonas maltophilia pneumonia in South Korea","volume":"38","author":"Lee","year":"2023","journal-title":"Acute Crit Care"},{"key":"2026020510355426200_dkag021-B24","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jmii.2023.03.001","article-title":"Appropriate antibiotic therapy is a predictor of outcome in patients with Stenotrophomonas maltophilia blood stream infection in the intensive care unit","volume":"56","author":"Lai","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"2026020510355426200_dkag021-B25","doi-asserted-by":"publisher","first-page":"e86294","DOI":"10.7759\/cureus.86294","article-title":"Determinants of clinical cure and mortality in patients with Stenotrophomonas maltophilia infections: a retrospective analysis","volume":"17","author":"Costa","year":"2025","journal-title":"Cureus"},{"key":"2026020510355426200_dkag021-B26","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1186\/s12879-024-10348-6","article-title":"Correction: evaluation of clinical outcomes and risk factors associated with mortality in patients with Stenotrophomonas maltophilia bloodstream infection: a multicenter study","volume":"24","author":"Gezer","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026020510355426200_dkag021-B27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/23744235.2024.2324365","article-title":"Risk factors for mortality in Stenotrophomonas maltophilia bacteremia\u2014a meta-analysis","volume":"56","author":"Huang","year":"2024","journal-title":"Infect Dis"},{"key":"2026020510355426200_dkag021-B28","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.3390\/jcm11113085","article-title":"Clinical characteristics, outcomes, and risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia","volume":"11","author":"Kanchanasuwan","year":"2022","journal-title":"J Clin Med"},{"key":"2026020510355426200_dkag021-B29","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1093\/jac\/dkaf131","article-title":"Antibiotic treatment of Stenotrophomonas maltophilia bacteraemia: does trimethoprim\/sulfamethoxazole dose affect clinical outcomes?","volume":"80","author":"Chen","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026020510355426200_dkag021-B30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.cmi.2018.11.008","article-title":"Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis","volume":"25","author":"Ko","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2026020510355426200_dkag021-B31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jgar.2017.09.015","article-title":"Sulfamethoxazole\/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections","volume":"12","author":"Watson","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2026020510355426200_dkag021-B32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1128\/AAC.01682-13","article-title":"Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?","volume":"58","author":"Cho","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020510355426200_dkag021-B33","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s15010-025-02512-0","article-title":"Clinical and microbiologic outcomes of Stenotrophomonas maltophilia bloodstream infections","volume":"53","author":"Shah","year":"2025","journal-title":"Infection"},{"key":"2026020510355426200_dkag021-B34","doi-asserted-by":"publisher","first-page":"ofad198","DOI":"10.1093\/ofid\/ofad198","article-title":"Correction to: trimethoprim-sulfamethoxazole versus levofloxacin for Stenotrophomonas maltophilia infections: a retrospective comparative effectiveness study of electronic health records from 154 US hospitals","volume":"10","author":"Anon","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026020510355426200_dkag021-B35","doi-asserted-by":"publisher","first-page":"ofab644","DOI":"10.1093\/ofid\/ofab644","article-title":"Trimethoprim-sulfamethoxazole versus levofloxacin for Stenotrophomonas maltophilia infections: a retrospective comparative effectiveness study of electronic health records from 154 US hospitals","volume":"9","author":"Sarzynski","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026020510355426200_dkag021-B36","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/jac\/dkaf024","article-title":"Comparison of trimethoprim-sulfamethoxazole versus minocycline monotherapy for treatment of Stenotrophomonas maltophilia pneumonia","volume":"80","author":"Graves","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026020510355426200_dkag021-B37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1186\/s12879-019-4394-4","article-title":"Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone\u2013resistant strains","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2026020510355426200_dkag021-B38","doi-asserted-by":"publisher","first-page":"e00855","DOI":"10.1128\/IAI.00855-19","article-title":"Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during polymicrobial airway infections","volume":"88","author":"McDaniel","year":"2020","journal-title":"Infect Immun"},{"key":"2026020510355426200_dkag021-B39","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/jac\/dkz116","article-title":"Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia","volume":"74","author":"Shah","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026020510355426200_dkag021-B40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/clinids\/22.3.508","article-title":"Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes","volume":"22","author":"Muder","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2026020510355426200_dkag021-B41","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s13054-019-2649-5","article-title":"Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study","volume":"23","author":"Guerci","year":"2019","journal-title":"Crit Care"},{"key":"2026020510355426200_dkag021-B42","doi-asserted-by":"publisher","first-page":"102759","DOI":"10.1016\/j.jiac.2025.102759","article-title":"Treatment of Stenotrophomonas malthophilia bloodstream infections from guidance to real life: multicenter retrospective cohort study","volume":"31","author":"Pascale","year":"2025","journal-title":"J Infect Chemother"},{"key":"2026020510355426200_dkag021-B43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13613-023-01144-7","article-title":"Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: a multicenter, observational, real-world study","volume":"13","author":"Chen","year":"2023","journal-title":"Ann Intensive Care"},{"key":"2026020510355426200_dkag021-B44","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/antibiotics11121788","article-title":"Combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis","volume":"11","author":"Prawang","year":"2022","journal-title":"Antibiotics"},{"key":"2026020510355426200_dkag021-B45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhin.2006.07.006","article-title":"Stenotrophomonas maltophilia and antibiotic use in German intensive care units: data from project SARI (surveillance of antimicrobial use and antimicrobial resistance in German intensive care units)","volume":"64","author":"Meyer","year":"2006","journal-title":"J Hosp Infect"},{"key":"2026020510355426200_dkag021-B46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.5005\/jp-journals-10071-24288","article-title":"Risk factors and clinical outcomes of Stenotrophomonas maltophilia infections: scenario in a tertiary care center from south India","volume":"26","author":"Varshini","year":"2022","journal-title":"Indian J Crit Care Med"},{"key":"2026020510355426200_dkag021-B47","doi-asserted-by":"publisher","first-page":"e26184","DOI":"10.7759\/cureus.26184","article-title":"Stenotrophomonas Maltophilia and urinary tract infections: a systematic review","volume":"14","author":"Umar","year":"2022","journal-title":"Cureus"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag021\/66725379\/dkag021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag021\/66725379\/dkag021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:35:59Z","timestamp":1770305759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag021\/8456268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag021","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag021"}}